Medium Risk

Morepen Laboratories Limited

Manufacturing, marketing and sale of pharmaceutical products and medical devices

CIN: L24231HP1984PLC006028 FY: - Revenue: ₹154,694.4 Cr
5.2
ESG Risk
Score /10
Compliance RiskEpr ExposureGhg Intensity

Risk Breakdown

GHG Intensity
5.0
Water Intensity
5.0
Waste Intensity
1.0
EPR Exposure
6.5
Compliance Risk
10.0
HR Risk
3.0
Governance Risk
3.0

Financial Exposure

Est. Compliance Cost₹248–928 crore
EPR ApplicableUnknown
Scope 1 Emissions— tCO2e
Scope 2 Emissions— tCO2e
Water Withdrawal— m³
Waste Generated4,394.1 T

Governance

Anti-Corruption PolicyYes
Conflict of Interest PolicyYes
BRSR AssuranceNone
Assurance Provider

Double Materiality

Financial Materiality5.2
Impact Materiality4.6
QuadrantFinancially Material

Supply Chain

MSME Sourcing0.0%
Lifecycle AssessmentNo
Product ReclaimYes

Material Risks

e-waste

ESG Targets & Commitments

TopicTarget / MetricStatus
Human Rights in Supply Chain HR clauses in all contracts Commitment

AI Risk Summary

Morepen Laboratories Limited carries a medium ESG financial risk score of 5.2/10. Primary risk drivers are compliance risk, epr exposure. Estimated annual compliance cost exposure: ₹248–928 crore.

Source: Morepen Laboratories Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.

← Back to ESG Quotient Dashboard Share on LinkedIn Browse all companies →